Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Alebund Pharmaceuticals (Jiangsu) Gross Margin %?
Alebund Pharmaceuticals (Jiangsu)HKSE:09637 -2.87%5 Gross Margin % is 44.00% as of Dec. 2025, which is 9% above its 10-year median of 40.27. GuruFocus rates HKSE:09637 with a GF Score™ of 5/100. The stock has 1 warning sign investors should review. Among 940 Drug Manufacturers companies, Alebund Pharmaceuticals (Jiangsu) ranks worse than 57.02% on this metric.
HKSE:09637's Gross Margin % is ranked worse than 57.02% of 940
companies
in the Drug Manufacturers industry
Industry Median: 48.45
vs HKSE:09637: 44.00
Alebund Pharmaceuticals (Jiangsu) had a gross margin of 44.00% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Alebund Pharmaceuticals (Jiangsu) had a gross margin of 44.00% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Alebund Pharmaceuticals (Jiangsu) Gross Margin % Related Terms
Alebund Pharmaceuticals (Jiangsu) Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Dec24
Dec25
Gross Margin %
36.54
44.00
HKSE:09637 vs LLY, JNJ, ABBV: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, Alebund Pharmaceuticals (Jiangsu)'s Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alebund Pharmaceuticals (Jiangsu) Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alebund Pharmaceuticals (Jiangsu)'s Gross Margin % distribution charts can be found below:
* The bar in red indicates where Alebund Pharmaceuticals (Jiangsu)'s Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a Gross Margin % of 44.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. This is near median its historical median of 40.27. Over the past decade, Alebund Pharmaceuticals (Jiangsu)'s Gross Margin % has ranged from 36.54 to 44.00. According to the industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #536 out of 940 companies in the Drug Manufacturers industry, placing it in the top 57%.
Is Alebund Pharmaceuticals (Jiangsu)'s Gross Margin % too high?
Alebund Pharmaceuticals (Jiangsu)'s current Gross Margin % of 44.00% is near median its 10-year median of 40.27. Over the past 10 years, this metric has ranged from a low of 36.54 to a high of 44.00. The Drug Manufacturers industry median Gross Margin % is 48.45. Alebund Pharmaceuticals (Jiangsu)'s value of 44.00% is 9.2% below this industry median. Based on the distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #536 out of 940 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s Gross Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #536 out of 940 companies for Gross Margin %. This places Alebund Pharmaceuticals (Jiangsu) in the lower half of its industry. The industry median Gross Margin % is 48.45. Alebund Pharmaceuticals (Jiangsu)'s value of 44.00% is 9.2% below this benchmark. Historically, Alebund Pharmaceuticals (Jiangsu)'s own Gross Margin % has ranged from 36.54 to 44.00 over the past decade. While the company's 10-year median is 40.27 vs. the industry median of 48.45, Alebund Pharmaceuticals (Jiangsu) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.45, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alebund Pharmaceuticals (Jiangsu)'s current Gross Margin % of 44.00% is 9.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alebund Pharmaceuticals (Jiangsu)'s current Gross Margin % is 44.00%, which is near median its own 10-year median of 40.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current Gross Margin % of 44.00%. The current Gross Margin % is 44.00%, which is near median its 10-year median of 40.27 and 9.2% below the Drug Manufacturers industry median of 48.45. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current Gross Margin % is 44.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score
Get the complete analysis for HKSE:09637
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09637 has been successfully added to your 
